AdaptHealth Corp. (AHCO) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
AdaptHealth Corp. (AHCO) slipped -1.66% to $5.93, trading at 9% of its 52-week range ($5.21 – $13.43). Stretched risk/reward at current multiples (2% return on capital) under elevated 10-year interest-rate pressure.
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on diluti
CONSHOHOCKEN, Pa., October 21, 2026--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medi
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AHCO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AHCO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, AdaptHealth Corp. (AHCO) ranks #476 by composite RQD confidence (45/100, grade D) and #386 by equity capitalization ($808.5M). Within this direct 5-issuer industry benchmark cohort, SBC leads on earnings valuation at 11.5x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with AHCO at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AHCO
ACTIVE
AdaptHealth Corp. | D | 45/100 | — | 18.8% | 2.2% | -1.66% | $808.5M | Benchmark Subject |
| STLN Starling Oncology Inc. | D- | 37/100 | — | — | -35.0% | +0.15% | $677.7M | /stln-vs-ahco → |
| SBC SBC Medical Group Holdings Incorporated | B- | 71/100 | 11.5x | 73.3% | 63.1% | +4.40% | $585.2M | /sbc-vs-ahco → |
| OMDA Omada Health Inc. | D+ | 56/100 | — | 65.7% | -15.7% | +2.45% | $1.20B | /omda-vs-ahco → |
| INNV InnovAge Holding Corp. | D+ | 57/100 | — | 18.0% | -10.2% | +1.54% | $1.26B | /innv-vs-ahco → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), AdaptHealth Corp. (AHCO) reported GAAP revenue of $3.24B (-0.5% vs. FY2024 revenue of $3.26B , and +1.4% cumulative change since FY2023) , GAAP net income of -$70.8M, operating cash flow of $601.8M, and free cash flow of $219.4M (-7.0% YoY). On the balance sheet, AHCO closed FY2025 with $4.32B in total assets against $1.72B in total debt (Altman Z-Score: 0.79, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.24B | -$70.8M | $601.8M | $219.4M | $4.32B | $1.72B |
| FY2024 (FY) | 2024-12-31 | $3.26B | $90.4M | $541.8M | $235.8M | $4.49B | $1.96B |
| FY2023 (FY) | 2023-12-31 | $3.20B | -$678.9M | $480.7M | $480.7M | — | — |
As of 2026-11-01, AdaptHealth Corp. (NASDAQ: AHCO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $5.93 (-1.66% 1D, market cap $808.5M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AHCO ranks #476 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), AHCO carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 18.8%, and ROIC of 2.2%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $677.7M) and SBC (SBC Medical Group Holdings Incorporated) posts a B- grade (71/100 RQD, P/E 11.5x, ROIC 63.1%, cap $585.2M). Among the 5-stock peer group, SBC leads on earnings multiple (11.5x) while SBC leads on capital efficiency (63.1% ROIC).
Per AHCO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001725255), AdaptHealth Corp. generated $3.24B in revenue (-0.5% YoY), -$70.8M in net income, and $219.4M in free cash flow against $4.32B in total assets and $1.72B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
AHCO last traded at $5.93 (-1.66% on volume of 2,084,597 shares), positioning the stock +0.85% above its 50-day simple moving average ($5.88) and -35.47% below its 200-day simple moving average ($9.19). Across its 52-week range of $5.21 to $13.43, AHCO sits at the 8.8% percentile with a 14-day RSI of 44.2 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($5.38 to $6.48).
Why AHCO Stock slipped -1.66% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (2% return on capital) under elevated 10-year interest-rate pressure.